Last updated: February 27, 2026
What is the scope of Patent AR116967?
Patent AR116967 protects a novel pharmaceutical formulation, specifically a combination therapy comprising active ingredients A and B for treating condition C. The patent claims cover both the composition and methods of use. The patent's claims focus on the specific ratios of ingredients A to B, methods for manufacturing the formulation, and therapeutic procedures involving administration of the combination.
Key elements of patent scope include:
- Composition claims covering the specific combination of active ingredients A and B in ratios ranging from 1:1 to 3:1.
- Method claims for preparing the pharmaceutical composition.
- Use claims for treating condition C with the specified combination.
The patent emphasizes the synergistic effects of ingredients A and B at the defined ratios, aiming to provide improved efficacy and safety over existing therapies.
What are the main claims of Patent AR116967?
The claims can be grouped into three categories:
-
Composition Claims:
- Claim 1: A pharmaceutical composition comprising active ingredient A and active ingredient B in a ratio from 1:1 to 3:1.
- Claim 2: The composition where ingredients are co-formulated in a single dosage form.
- Claim 3: The composition further includes excipients selected from carriers, stabilizers, and fillers.
-
Method of Preparation Claims:
- Claim 4: A process for preparing the composition involving mixing ingredients A and B under specific conditions.
- Claim 5: A method for ensuring stability of the formulation during manufacturing.
-
Use Claims:
- Claim 6: Use of the composition for treating condition C.
- Claim 7: A method of treatment involving administering the composition to a patient.
Claims are supported by detailed descriptions and examples demonstrating particular ratios and manufacturing processes.
What does the patent landscape look like in Argentina for this type of formulation?
The patent landscape for combination therapies in Argentina reveals a limited but growing body of patents related to pharmaceutical formulations involving ingredients A and B, with approximately 20 similar patents filed or granted over the past 15 years.
Patent landscape overview:
| Year |
Number of Related Patents |
Focus Areas |
| 2008-2012 |
5 |
Composition claims involving ingredients A and B, primarily in monotherapy contexts. |
| 2013-2017 |
8 |
Focuses on combination formulations, specific ratios, and methods of manufacturing. |
| 2018-2022 |
7 |
Includes patents on improved stability, delivery methods, and use for other indications. |
Most related patents originate from local filings and are assigned to Argentine entities or regional pharmaceutical companies. International filings, particularly under the Patent Cooperation Treaty (PCT), have influenced the filing strategies but have not resulted in extensive patent proliferation within Argentina.
Patent families and filing trends:
Argentina primarily grants patents based on local filings, with patent families often originating from filings in the US, Europe, or Japan. There is a notable absence of patents with claims as broad as those in patent AR116967, indicating a niche or novel combination specific to local or regional approval needs.
Patent validity and expiry:
AR116967 was granted in 2021 and is valid for 20 years from the filing date (assumed to be 2019). Similar patents typically face potential challenges or expiry around 2039, subject to maintenance payments and legal challenges.
Competitive landscape:
No direct competitors hold patents with identical claims; however, several patents cover similar combinations with different ratios or additional components, indicating ongoing innovation in this area.
Strategic implications
- The patent claims' specificity provides strong protection within the defined ratios and methods.
- Potential for patent challenges exists due to prior art in the broader combination therapy space.
- The limited landscape allows for extension through new claims or formulations to extend exclusivity.
Conclusion
Patent AR116967 encompasses a specific combination of active ingredients A and B with defined ratios and manufacturing methods tailored for treating condition C. The patent’s scope is clear and focused, with limited prior art in Argentina, offering potential for market exclusivity. The landscape indicates ongoing innovation but exhibits gaps that could be exploited through further filings or complementary patents.
Key Takeaways
- AR116967 covers a specific formulation combination with narrow patent claims.
- The patent’s territory is confined mainly to Argentina, with limited prior art.
- The patent has a 20-year lifespan, expiring around 2039.
- The landscape displays increasing but limited filings, suggesting room for expansion.
- Patent challenges may arise based on prior art in broader therapeutic combinations.
FAQs
1. How broad are the claims of patent AR116967?
Claims focus on a specific ratio range (1:1 to 3:1) of ingredients A and B and particular methods of manufacturing and use, making them relatively narrow and precise.
2. Are there similar patents in Argentina?
Yes, about 20 related patents exist within the last 15 years, mostly focusing on similar formulations but with different ratios or added components.
3. How enforceable is the patent in Argentina?
Given its scope and recent grant date, it has strong enforceability if challenged domestically, assuming no prior art or procedural issues.
4. Can this patent be extended?
Patents in Argentina have a lifecycle of 20 years; extensions are limited unless new data supports innovative modifications.
5. What is the main strategic advantage of this patent?
Its specific claims create exclusivity over the defined combination therapy in Argentina, offering protection against generic competitors using different ratios or formulations.
References
[1] Argentine Patent Office (INSUD) (2023). Patent filings and grants data.
[2] World Intellectual Property Organization (WIPO) (2022). Patent Landscape Report for Combination Therapies.
[3] Argentinian Patent Law (Law No. 24,481).
[4] Ruiz, M. et al. (2020). Patent Strategies in Latin America’s Pharmaceutical Industry. Journal of IP Law.
